Zoetis (ZTS) 10-K Summary — Year Ended Dec 31, 2024

Zoetis Inc. filed its annual report for the fiscal year ended December 31, 2024. The company reported revenue growth and net income, with operating cash flow supporting its financial position.

Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostics. It operates globally with a focus on both livestock and companion animals, serving veterinarians and livestock producers. The company's business segments and product lines are detailed in the filing, along with its research and development, manufacturing, and regulatory activities.

Revenue increased compared to the prior year, and net income was reported. Operating cash flow was positive, reflecting the company's ability to generate cash from its operations. The filing notes that inventories decreased due to a divestiture and higher-than-anticipated sales for certain products.

The filing identifies risk factors in Item 1A, including those related to regulatory changes, competition, intellectual property, and international operations. The company also faces risks from manufacturing and supply chain disruptions, as well as potential asset impairment charges. These risks are described in the risk factors section without exaggeration.

Capital spending increased property, plant, and equipment, partially offset by depreciation and a divestiture. The company also had a prepayment from a related foreign entity in Belgium, affecting other current assets. No explicit capital allocation strategy beyond these items is discussed in the supplied context.

Monitor the impact of the divestiture of the medicated feed additive product portfolio on future revenue and inventory levels.